دورية أكاديمية
أعرض في EDS

Advances in the Understanding of Skin Cancer: Ultraviolet Radiation, Mutations, and Antisense Oligonucleotides as Anticancer Drugs.

التفاصيل البيبلوغرافية
العنوان: Advances in the Understanding of Skin Cancer: Ultraviolet Radiation, Mutations, and Antisense Oligonucleotides as Anticancer Drugs.
المؤلفون: Laikova KV; Medical Academy named after S.I. Georgievsky, V.I. Vernadsky Crimean Federal University, Lenin Boulevard 5/7, 295051 Simferopol, Crimea. botan_icus@mail.ru.; Research Institute of Agriculture of Crimea, Kiyevskaya St. 150, 295493, Simferopol, Crimea. botan_icus@mail.ru., Oberemok VV; Taurida Academy, V.I. Vernadsky Crimean Federal University, Vernadsky Av. 4, 295007 Simferopol, Crimea. genepcr@mail.ru.; Nikita Botanical Gardens ⁻ National Scientific Centre RAS, Nikitsky spusk 52, vil. Nikita, 298648 Yalta, Crimea. genepcr@mail.ru., Krasnodubets AM; Taurida Academy, V.I. Vernadsky Crimean Federal University, Vernadsky Av. 4, 295007 Simferopol, Crimea. akrasnodubets@gmail.com., Gal'chinsky NV; Taurida Academy, V.I. Vernadsky Crimean Federal University, Vernadsky Av. 4, 295007 Simferopol, Crimea. pcr.product@gmail.com., Useinov RZ; Taurida Academy, V.I. Vernadsky Crimean Federal University, Vernadsky Av. 4, 295007 Simferopol, Crimea. useinovrefat@gmail.com., Novikov IA; Taurida Academy, V.I. Vernadsky Crimean Federal University, Vernadsky Av. 4, 295007 Simferopol, Crimea. i.nowikow2012@mail.ru., Temirova ZZ; Medical Academy named after S.I. Georgievsky, V.I. Vernadsky Crimean Federal University, Lenin Boulevard 5/7, 295051 Simferopol, Crimea. wwwzzznnn333@gmail.com., Gorlov MV; D. Mendeleev University of Chemical Technology of Russia, Miusskaya sq. 9, 125047 Moscow, Russia. mikgorlov@gmail.com., Shved NA; Centre for Genomic and Regenerative Medicine, School of Biomedicine, Far Eastern Federal University, Sukhanova St. 8, 690090 Vladivostok, Russia. nikitawayfarer@yandex.ru.; National Scientific Center of Marine Biology, Far Eastern Branch of Russian Academy of Sciences, Palchevsky St. 17, 690041 Vladivostok, Russia. nikitawayfarer@yandex.ru., Kumeiko VV; Centre for Genomic and Regenerative Medicine, School of Biomedicine, Far Eastern Federal University, Sukhanova St. 8, 690090 Vladivostok, Russia. vkumeiko@yandex.ru.; National Scientific Center of Marine Biology, Far Eastern Branch of Russian Academy of Sciences, Palchevsky St. 17, 690041 Vladivostok, Russia. vkumeiko@yandex.ru., Makalish TP; Medical Academy named after S.I. Georgievsky, V.I. Vernadsky Crimean Federal University, Lenin Boulevard 5/7, 295051 Simferopol, Crimea. gemini_m@list.ru., Bessalova EY; Medical Academy named after S.I. Georgievsky, V.I. Vernadsky Crimean Federal University, Lenin Boulevard 5/7, 295051 Simferopol, Crimea. evgu79@mail.ru., Fomochkina II; Medical Academy named after S.I. Georgievsky, V.I. Vernadsky Crimean Federal University, Lenin Boulevard 5/7, 295051 Simferopol, Crimea. fomochkina_i@mail.ru., Esin AS; D. Mendeleev University of Chemical Technology of Russia, Miusskaya sq. 9, 125047 Moscow, Russia. sin.sad92@gmail.com., Volkov ME; Ltd 'NPF Syntol', Тimiryazevskaya St. 42, 127434 Moscow, Russia. mikki1@mail.ru., Kubyshkin AV; Medical Academy named after S.I. Georgievsky, V.I. Vernadsky Crimean Federal University, Lenin Boulevard 5/7, 295051 Simferopol, Crimea. kubyshkin_av@mail.ru.
المصدر: Molecules (Basel, Switzerland) [Molecules] 2019 Apr 17; Vol. 24 (8). Date of Electronic Publication: 2019 Apr 17.
نوع المنشور: Journal Article; Review
اللغة: English
بيانات الدورية: Publisher: MDPI Country of Publication: Switzerland NLM ID: 100964009 Publication Model: Electronic Cited Medium: Internet ISSN: 1420-3049 (Electronic) Linking ISSN: 14203049 NLM ISO Abbreviation: Molecules
أسماء مطبوعة: Original Publication: Basel, Switzerland : MDPI, c1995-
مواضيع طبية MeSH: Melanoma*/drug therapy , Melanoma*/metabolism , Melanoma*/pathology , Mutation* , Skin Neoplasms*/drug therapy , Skin Neoplasms*/metabolism , Skin Neoplasms*/pathology, Antineoplastic Agents/*therapeutic use , Oligonucleotides, Antisense/*therapeutic use , Ultraviolet Rays/*adverse effects, Apoptosis/drug effects ; Apoptosis/radiation effects ; Cell Transformation, Neoplastic/drug effects ; Cell Transformation, Neoplastic/radiation effects ; Humans
مستخلص: Skin cancer has always been and remains the leader among all tumors in terms of occurrence. One of the main factors responsible for skin cancer, natural and artificial UV radiation, causes the mutations that transform healthy cells into cancer cells. These mutations inactivate apoptosis, an event required to avoid the malignant transformation of healthy cells. Among these deadliest of cancers, melanoma and its 'younger sister', Merkel cell carcinoma, are the most lethal. The heavy toll of skin cancers stems from their rapid progression and the fact that they metastasize easily. Added to this is the difficulty in determining reliable margins when excising tumors and the lack of effective chemotherapy. Possibly the biggest problem posed by skin cancer is reliably detecting the extent to which cancer cells have spread throughout the body. The initial tumor is visible and can be removed, whereas metastases are invisible to the naked eye and much harder to eliminate. In our opinion, antisense oligonucleotides, which can be used in the form of targeted ointments, provide real hope as a treatment that will eliminate cancer cells near the tumor focus both before and after surgery.
Competing Interests: The authors have no conflicts of interest.
References: Pharm Res. 2004 Dec;21(12):2219-25. (PMID: 15648253)
P T. 2014 Feb;39(2):119-22. (PMID: 24669178)
Clin Cancer Res. 2010 Dec 15;16(24):6150-8. (PMID: 21041181)
Nat Med. 1998 Feb;4(2):232-4. (PMID: 9461199)
Cancers (Basel). 2016 Oct 22;8(10):. (PMID: 27782094)
Future Oncol. 2007 Jun;3(3):263-71. (PMID: 17547520)
Am J Surg Pathol. 2009 Sep;33(9):1378-85. (PMID: 19609205)
J Am Acad Dermatol. 2012 Oct;67(4):531-50. (PMID: 22959232)
Adv Drug Deliv Rev. 2000 Oct 31;44(1):51-7. (PMID: 11035197)
N Engl J Med. 2012 Feb 23;366(8):707-14. (PMID: 22356324)
Drug Des Devel Ther. 2017 Feb 28;11:533-545. (PMID: 28280301)
J Drug Target. 1998;5(4):275-89. (PMID: 9713977)
N Engl J Med. 2010 Aug 26;363(9):809-19. (PMID: 20818844)
Cell Mol Biol (Noisy-le-grand). 1999 Nov;45(7):1011-27. (PMID: 10644005)
Onco Targets Ther. 2017 Aug 08;10:3941-3947. (PMID: 28860801)
Br J Dermatol. 2017 Oct;177(4):936-944. (PMID: 28278349)
Eur J Cancer. 2017 Jan;71:53-69. (PMID: 27984768)
Molecules. 2018 May 29;23(6):. (PMID: 29844255)
Int J Pharm. 2008 Dec 8;364(2):237-48. (PMID: 18619528)
Nature. 2011 Jan 20;469(7330):314-22. (PMID: 21248838)
Ann Surg Oncol. 2016 Apr;23(4):1053-6. (PMID: 26561402)
Adv Anat Embryol Cell Biol. 2012;212:v, vii, 1-115. (PMID: 22894052)
Int J Cancer. 2002 May 20;99(3):352-60. (PMID: 11992403)
Ocul Immunol Inflamm. 1999 Dec;7(3-4):189-98. (PMID: 10611727)
Am J Kidney Dis. 2011 Feb;57(2):300-3. (PMID: 21177011)
J Invest Dermatol. 2000 Nov;115(5):805-12. (PMID: 11069617)
Int J Mol Sci. 2013 Jun 07;14(6):12222-48. (PMID: 23749111)
Oncogene. 2014 Feb 27;33(9):1158-66. (PMID: 23455323)
J Clin Invest. 1995 Apr;95(4):1814-23. (PMID: 7706488)
Curr Treat Options Oncol. 2013 Jun;14(2):249-63. (PMID: 23436166)
J Exp Clin Cancer Res. 2000 Mar;19(1):21-34. (PMID: 10840932)
Dermatol Pract Concept. 2017 Apr 30;7(2):1-6. (PMID: 28515985)
Int J Cancer. 1997 Oct 9;73(2):198-203. (PMID: 9335442)
J Surg Oncol. 2011 Sep;104(4):341-53. (PMID: 21858828)
Am J Hum Genet. 2004 Nov;75(5):739-51. (PMID: 15372380)
N Engl J Med. 2010 Aug 19;363(8):711-23. (PMID: 20525992)
J Invest Dermatol. 2008 Aug;128(8):2024-30. (PMID: 18323782)
Dermatoendocrinol. 2012 Apr 1;4(2):109-17. (PMID: 22928066)
Carcinogenesis. 2007 Jun;28(6):1133-9. (PMID: 17341657)
Curr Opin Virol. 2012 Aug;2(4):489-98. (PMID: 22710026)
Am J Infect Control. 1982 May;10(2):53-9. (PMID: 7044193)
Exp Dermatol. 2009 Mar;18(3):193-8. (PMID: 19400830)
Nat Rev Cancer. 2008 Oct;8(10):743-54. (PMID: 18813320)
J Control Release. 2006 Oct 27;115(3):344-53. (PMID: 17005286)
Cancer Treat Rev. 2009 Nov;35(7):553-62. (PMID: 19559538)
Front Genet. 2016 May 31;7:95. (PMID: 27303435)
Cancer. 2012 Aug 15;118(16):4014-23. (PMID: 22180178)
Dermatol Clin. 2006 Jan;24(1):9-17. (PMID: 16311163)
Nat Med. 1995 Nov;1(11):1119-21. (PMID: 7584974)
Am J Dermatopathol. 1996 Jun;18(3):273-7. (PMID: 8806961)
Semin Oncol. 2002 Oct;29(5):427-45. (PMID: 12407508)
Nature. 2010 Jan 14;463(7278):191-6. (PMID: 20016485)
Antisense Nucleic Acid Drug Dev. 2002 Jun;12(3):193-213. (PMID: 12162702)
Annu Rev Med. 2012;63:171-83. (PMID: 22034865)
Ther Clin Risk Manag. 2007 Oct;3(5):855-70. (PMID: 18473009)
Cell. 1998 Aug 21;94(4):481-90. (PMID: 9727491)
J Invest Dermatol. 2008 Nov;128(11):2716-2727. (PMID: 18509359)
G Ital Dermatol Venereol. 2010 Apr;145(2):309-11. (PMID: 20467403)
Dermatol Surg. 2012 Apr;38(4):537-51. (PMID: 22288484)
Cancer Lett. 2015 Apr 1;359(1):20-35. (PMID: 25597784)
J Natl Compr Canc Netw. 2014 Sep;12(9):1255-62. (PMID: 25190694)
Nat Clin Pract Oncol. 2008 Sep;5(9):557-61. (PMID: 18665147)
J Transl Med. 2012 Jul 09;10:85. (PMID: 22554099)
J Control Release. 2015 Dec 10;219:445-456. (PMID: 26385169)
Nat Rev Cancer. 2008 May;8(5):377-86. (PMID: 18385683)
Adv Pharmacol. 2012;65:361-98. (PMID: 22959032)
Semin Cutan Med Surg. 2011 Mar;30(1):48-56. (PMID: 21540020)
J Invest Dermatol. 1999 Dec;113(6):1076-81. (PMID: 10594755)
Nat Cell Biol. 2010 Mar;12(3):299-305. (PMID: 20154679)
J Invest Dermatol. 2013 May;133(5):1161-9. (PMID: 23407391)
Lancet Oncol. 2016 Feb;17(2):127-128. (PMID: 26790923)
Br J Dermatol. 2011 Nov;165(5):953-65. (PMID: 21729024)
Oncogene. 2003 May 19;22(20):3138-51. (PMID: 12789290)
PLoS One. 2014 Dec 11;9(12):e111920. (PMID: 25502446)
Oncotarget. 2016 Apr 26;7(17):23454-67. (PMID: 26981779)
Cell. 1994 Aug 26;78(4):539-42. (PMID: 8069905)
Clin Oncol (R Coll Radiol). 2015 Aug;27(8):436-44. (PMID: 26009549)
J Clin Aesthet Dermatol. 2017 Apr;10(4):37-46. (PMID: 28458773)
Cancers (Basel). 2014 Oct 17;6(4):2116-36. (PMID: 25329450)
Science. 2008 Feb 22;319(5866):1096-100. (PMID: 18202256)
Adv Exp Med Biol. 2008;624:89-103. (PMID: 18348450)
J Clin Med. 2015 Jun 03;4(6):1229-39. (PMID: 26239556)
Pharm Res. 2002 Oct;19(10):1465-70. (PMID: 12425463)
J Invest Dermatol. 2014 Oct;134(10):2491-2493. (PMID: 25219650)
Pharm Res. 2001 Dec;18(12):1789-93. (PMID: 11785702)
Lancet. 2002 Feb 9;359(9305):497-8. (PMID: 11853800)
Clinics (Sao Paulo). 2011;66(10):1817-23. (PMID: 22012057)
Nat Rev Cancer. 2003 Oct;3(10):768-80. (PMID: 14570043)
APMIS. 2014 Dec;122(12):1157-66. (PMID: 24735260)
J Clin Oncol. 2005 Feb 1;23(4):866-73. (PMID: 15681532)
Trends Mol Med. 2012 Jan;18(1):27-35. (PMID: 21962474)
Ann Surg Oncol. 2013 Jan;20(1):346-51. (PMID: 23010731)
Arch Dermatol. 2001 Nov;137(11):1486-92. (PMID: 11708952)
Cancer Res. 2015 Dec 15;75(24):5228-34. (PMID: 26627015)
Nature. 2007 Feb 22;445(7130):834-42. (PMID: 17314969)
Dermatol Surg. 2009 Sep;35(9):1311-23. (PMID: 19496793)
Head Neck Pathol. 2015 Mar;9(1):127-34. (PMID: 24496654)
J Invest Dermatol. 2007 Sep;127(9):2100-3. (PMID: 17700621)
Nat Rev Dis Primers. 2017 Oct 26;3:17077. (PMID: 29072302)
J Invest Dermatol. 2014 Oct;134(10):2497-2502. (PMID: 24804836)
Occup Med (Lond). 2009 Mar;59(2):82-8. (PMID: 19233827)
Mutat Res. 2010 Oct;705(2):141-153. (PMID: 20601102)
J Invest Dermatol. 2002 Jun;118(6):1003-7. (PMID: 12060395)
Br J Dermatol. 2011 Nov;165(5):1051-7. (PMID: 21711338)
PLoS Pathog. 2010 Aug 26;6(8):e1001076. (PMID: 20865165)
Lancet. 2002 Jun 8;359(9322):1999-2000. (PMID: 12076557)
Curr Pharmacol Rep. 2015 Jun 1;1(3):206-215. (PMID: 26097804)
J Invest Dermatol. 2015 Sep;135(9):2155-2161. (PMID: 25947358)
Ann Oncol. 2006 Feb;17(2):313-21. (PMID: 16322117)
Int J Mol Sci. 2017 Nov 17;18(11):. (PMID: 29149051)
Genes Dev. 2006 Aug 15;20(16):2149-82. (PMID: 16912270)
J Med Genet. 2004 Apr;41(4):270-2. (PMID: 15060100)
In Vitro Cell Dev Biol Anim. 1993 Apr;29A(4):258-60. (PMID: 8320176)
Cell Death Differ. 2009 Mar;16(3):360-7. (PMID: 18806758)
Proc Natl Acad Sci U S A. 2011 Sep 20;108(38):15816-21. (PMID: 21903933)
Int J Dermatol. 2010 Sep;49(9):978-86. (PMID: 20883261)
Int J Cancer. 2001 Sep 1;93(5):617-22. (PMID: 11477569)
Proc Natl Acad Sci U S A. 1974 Sep;71(9):3363-6. (PMID: 4530308)
Cancer Metastasis Rev. 2001;20(1-2):3-11. (PMID: 11831644)
J Invest Dermatol. 2002 Mar;118(3):505-12. (PMID: 11874491)
J Clin Oncol. 2006 Oct 10;24(29):4738-45. (PMID: 16966688)
Expert Rev Dermatol. 2008 Oct;3(5):569-585. (PMID: 19649148)
Br J Dermatol. 2002 Apr;146 Suppl 61:1-6. (PMID: 11966724)
Pathology. 2014 Apr;46(3):205-10. (PMID: 24614722)
Ann Surg. 1999 Jan;229(1):97-105. (PMID: 9923806)
JAMA Dermatol. 2017 Feb 1;153(2):225-226. (PMID: 28002545)
J Natl Compr Canc Netw. 2014 Mar 1;12(3):434-41. (PMID: 24616547)
Nanoscale. 2015 Mar 7;7(9):3903-14. (PMID: 25436837)
Br J Dermatol. 2017 Jul;177(1):134-140. (PMID: 28369739)
Oncotarget. 2017 Jan 24;8(4):6873-6882. (PMID: 28036288)
J Invest Dermatol. 2012 Mar;132(3 Pt 2):854-63. (PMID: 22217739)
Front Biosci. 2006 May 01;11:1244-54. (PMID: 16368510)
Nat Med. 2002 Aug;8(8):793-800. (PMID: 12091876)
Am J Clin Oncol. 2009 Apr;32(2):174-9. (PMID: 19307957)
Lancet. 2000 Nov 18;356(9243):1728-33. (PMID: 11095261)
Cancer Gene Ther. 2001 Jun;8(6):459-68. (PMID: 11498766)
Am Surg. 2015 Aug;81(8):802-6. (PMID: 26215243)
J Natl Compr Canc Netw. 2012 Mar;10(3):312-8. (PMID: 22393193)
Dermatol Surg. 2014 Dec;40(12):1273-83. (PMID: 25350122)
Cancer Biol Med. 2015 Dec;12(4):375-84. (PMID: 26779374)
J Invest Dermatol. 2014 Feb;134(2):507-517. (PMID: 23962809)
J Clin Oncol. 2004 Mar 15;22(6):1118-25. (PMID: 15020614)
Head Face Med. 2016 Feb 05;12:11. (PMID: 26850723)
J Invest Dermatol. 2013 Aug;133(8):2041-9. (PMID: 23344460)
Melanoma Res. 1999 Feb;9(1):51-8. (PMID: 10338334)
Front Chem. 2014 Oct 14;2:87. (PMID: 25353019)
J Invest Dermatol. 2000 Apr;114(4):725-30. (PMID: 10733680)
J Am Acad Dermatol. 2010 Nov;63(5):751-61. (PMID: 20646783)
Leuk Lymphoma. 2009 Mar;50(3):335-40. (PMID: 19255922)
N Engl J Med. 2005 Nov 17;353(20):2135-47. (PMID: 16291983)
Br J Dermatol. 2012 May;166(5):1069-80. (PMID: 22251204)
Cytokine Growth Factor Rev. 2015 Apr;26(2):203-12. (PMID: 25511547)
J Clin Oncol. 2001 Aug 15;19(16):3635-48. (PMID: 11504745)
Ann Surg Oncol. 2011 Feb;18(2):328-36. (PMID: 20844969)
Melanoma Res. 2001 Apr;11(2):189-96. (PMID: 11333130)
Nat Rev Cancer. 2002 Sep;2(9):647-56. (PMID: 12209154)
Int J Pharm. 1999 Jul 20;184(2):147-56. (PMID: 10387943)
Cancer Res. 2000 Apr 1;60(7):1968-73. (PMID: 10766187)
Cancers (Basel). 2016 Oct 04;8(10):. (PMID: 27782043)
Cancer Treat Rev. 2013 Aug;39(5):421-9. (PMID: 23375558)
Biomed Res Int. 2015;2015:642549. (PMID: 26688814)
Gastroenterology. 1998 Jun;114(6):1133-42. (PMID: 9609749)
PLoS One. 2010 Jul 02;5(7):e11423. (PMID: 20625394)
Clin Med Oncol. 2008;2:327-33. (PMID: 21892294)
Oncotarget. 2018 Jan 3;9(15):12452-12470. (PMID: 29552325)
Mol Ther. 2017 May 3;25(5):1069-1075. (PMID: 28366767)
Nat Med. 1997 Aug;3(8):917-21. (PMID: 9256286)
Hautarzt. 2010 Dec;61(12):1052-5. (PMID: 20824263)
EMBO J. 2003 Jun 2;22(11):2729-40. (PMID: 12773388)
Ann Oncol. 2011 Feb;22(2):250-6. (PMID: 20587511)
J Am Acad Dermatol. 2008 Mar;58(3):375-81. (PMID: 18280333)
Br J Dermatol. 2011 Apr;164(4):776-84. (PMID: 21166657)
Endocr Rev. 2000 Oct;21(5):457-87. (PMID: 11041445)
Toxicol Appl Pharmacol. 2007 Nov 1;224(3):241-8. (PMID: 17270229)
J Drugs Dermatol. 2017 May 1;16(5):464-469. (PMID: 28628682)
Proc Am Thorac Soc. 2009 Apr 15;6(2):187-93. (PMID: 19349487)
J Invest Dermatol. 2005 May;124(5):971-5. (PMID: 15854038)
Am Soc Clin Oncol Educ Book. 2015;:e519-26. (PMID: 25993218)
J Cell Biochem. 2017 Nov;118(11):3686-3695. (PMID: 28370183)
Pharmacol Ther. 2001 Apr;90(1):89-104. (PMID: 11448727)
J Pharm Sci. 1997 Sep;86(9):1022-9. (PMID: 9294816)
Cell Stem Cell. 2015 Apr 2;16(4):400-12. (PMID: 25842978)
Semin Cutan Med Surg. 2014 Jun;33(2):76-82. (PMID: 25085666)
Hum Pathol. 1999 Nov;30(11):1367-72. (PMID: 10571519)
J Skin Cancer. 2012;2012:680410. (PMID: 23304516)
Mod Pathol. 2004 May;17(5):561-7. (PMID: 15001998)
Lancet. 2002 Jun 1;359(9321):1921-2. (PMID: 12057558)
Biomaterials. 2014 Mar;35(10):3435-42. (PMID: 24424208)
فهرسة مساهمة: Keywords: Merkel cell carcinoma; antisense oligonucleotides; basal cell carcinoma; dermatofibrosarcoma protuberans; melanoma; mutations; skin; squamous cell carcinoma; ultraviolet radiation
المشرفين على المادة: 0 (Antineoplastic Agents)
0 (Oligonucleotides, Antisense)
تواريخ الأحداث: Date Created: 20190420 Date Completed: 20190806 Latest Revision: 20240716
رمز التحديث: 20240716
مُعرف محوري في PubMed: PMC6514765
DOI: 10.3390/molecules24081516
PMID: 30999681
قاعدة البيانات: MEDLINE
الوصف
تدمد:1420-3049
DOI:10.3390/molecules24081516